尼达尼布治疗接受麦考酚酯的系统性硬化相关间质性肺病患者的疗效与安全性:SENSCIS试验亚组分析
SENSCIS试验亚组分析纳入576例系统性硬化相关间质性肺病(SSc-ILD)患者,随机接受尼达尼布或安慰剂至少52周。不良事件谱相似。
要点
- 尼达尼布在基线使用或未使用麦考酚酯的SSc-ILD患者中均减缓FVC下降,亚组间无显著异质性。
- 尼达尼布不良事件谱在麦考酚酯亚组间相似,提示联合治疗安全性可接受。
核心结论
- 尼达尼布在基线使用和未使用麦考酚酯的SSc-ILD患者中均减缓间质性肺病进展,亚组间治疗效应无显著异质性。
- 尼达尼布不良事件谱在麦考酚酯使用亚组间相似。
- 研究提示麦考酚酯与尼达尼布联合为SSc-ILD患者提供安全治疗选择。
- 初始联合治疗与序贯治疗的优势比较仍需更多数据。
研究设计与样本
- SENSCIS为随机、双盲、安慰剂对照试验,患者按1:1随机接受口服尼达尼布150 mg每日两次或安慰剂至少52周。
- 共筛查819例,纳入576例,尼达尼布组288例,安慰剂组288例。
- 基线使用麦考酚酯者:尼达尼布组139/288例(48%),安慰剂组140/288例(49%)。
- 分析纳入所有至少接受一剂研究药物的参与者。
关键数值与推荐
- 主要终点:52周FVC年下降率,使用随机系数回归模型分析,协变量包括抗拓扑异构酶I抗体状态、年龄、身高、性别和基线FVC。
- 腹泻最常见不良事件:基线使用麦考酚酯者尼达尼布组106/139(76%) vs 安慰剂组48/140(34%);未使用者尼达尼布组112/149(75%) vs 安慰剂组43/148(29%)。
- 整个试验期间死亡19例(尼达尼布组10例,安慰剂组9例),尼达尼布组1例死亡被认为与研究药物相关。
临床怎么用
- 对于SSc-ILD患者,无论基线是否使用麦考酚酯,尼达尼布均可考虑用于减缓FVC下降。
- 尼达尼布与麦考酚酯联合治疗的安全性在亚组间相似,支持联合用药。
- 临床决策需结合患者个体情况,初始联合与序贯治疗的选择尚需更多证据。
局限性
- 研究未直接比较初始联合治疗与序贯治疗的优势。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Patients on stable treatment with mycophenolate for at least 6 months before randomisation could participate. The aim of this subgroup analysis was to examine the efficacy and safety of nintedanib by mycophenolate use at baseline. METHODS: The SENSCIS trial was a randomised, double-blind, placebo-controlled trial, in which patients with SSc-ILD were randomly assigned (1:1) to receive 150 mg of oral nintedanib twice daily or placebo for at least 52 weeks. In a prespecified subgroup analysis, we analysed the primary endpoint of rate of decline in FVC over 52 weeks by mycophenolate use at baseline. In a post-hoc analysis, we analysed the proportion of patients with an absolute decrease in FVC of at least 3·3% predicted at week 52 (proposed minimal clinically important difference estimate for worsening of FVC in patients with SSc-ILD) in subgroups by mycophenolate use at baseline. Adverse events were reported in subgroups by mycophenolate use at baseline. Analyses were done in all participants who received at least one dose of study drug. We analysed the annual rate of decline in FVC using a random coefficient regression model (with random slopes and intercepts) including anti-topoisomerase I antibody status, age, height, sex, and baseline FVC as covariates and terms for baseline-by-time, treatment-by-subgroup, and treatment-by-subgroup-by-time interactions. SENSCIS is registered with ClinicalTrials.gov, NCT02597933, and is now complete. FINDINGS: Between Nov 30, 2015, and Oct 31, 2017, 819 participants were screened and 576 were enrolled, randomly assigned to, and treated with nintedanib (n=288) or placebo (n=288). 139 (48%) of 288 in the nintedanib group and 140 (49%) of 288 in the placebo group were taking mycophenolate at baseline. In patients taking mycophenolate at baseline, the adjusted mean annual rate of decline in FVC was -40·2 mL per year (SE 19·8) with nintedanib and -66·5 mL per year (19·3) with placebo (difference: 26·3 mL per year [95% CI -27·9 to 80·6]). In patients not taking mycophenolate at baseline, the adjusted mean annual rate of decline in FVC was -63·9 mL per year (SE 19·3) with nintedanib and -119·3 mL per year (19·0) with placebo (difference: 55·4 mL per year [95% CI 2·3 to 108·5]). We found no heterogeneity in the effect of nintedanib versus placebo on the annual rate of decline in FVC between the subgroups by mycophenolate use (p value for interaction=0·45). In a post-hoc analysis, the proportion of patients with an absolute decrease in FVC of at least 3·3% predicted was lower with nintedanib than with placebo in both patients taking mycophenolate (40 [29%] of 138 vs 56 [40%] of 140; odds ratio 0·61 [0·37 to 1·01]) and those not taking mycophenolate (59 [40%] of 149 vs 70 [47%] of 148; 0·73 [0·46 to 1·16]) at baseline. The adverse event profile of nintedanib was similar between the subgroups. Diarrhoea, the most common adverse event, was reported in 106 (76%) of 139 patients in the nintedanib group and 48 (34%) of 140 in the placebo group among those taking mycophenolate at baseline, and in 112 (75%) of 149 in the nintedanib group and 43 (29%) of 148 in the placebo group among those not taking mycophenolate at baseline. Over the entire trial period, 19 patients died (ten in the nintedanib group and nine in the placebo group). One death in the nintedanib group was considered to be related to study drug. INTERPRETATION: Nintedanib reduced the progression of interstitial lung disease both in patients with SSc-ILD who were and were not using mycophenolate at baseline, with no heterogeneity in its treatment effect detected between the subgroups. The adverse event profile of nintedanib was similar in the subgroups by mycophenolate use. Our findings suggest that the combination of mycophenolate and nintedanib offers a safe treatment option for patients with SSc-ILD. More data are needed on the benefits of initial combination therapy versus a sequential approach to treatment of SSc-ILD. FUNDING: Boehringer Ingelheim.
引用
- Highland KB, Distler O, Kuwana M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021. PMID: 33412120. doi:10.1016/S2213-2600(20)30330-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。